We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Blood-Based Test Allows for Minimally Invasive Detection of IDH1.R132H-Mutant Gliomas

By LabMedica International staff writers
Posted on 04 Sep 2024
Print article
Image: A blood-based assay has been developed for the detection of IDH1.R132H-mutant gliomas (Photo courtesy of 123RF)
Image: A blood-based assay has been developed for the detection of IDH1.R132H-mutant gliomas (Photo courtesy of 123RF)

Glioma is the most prevalent type of central nervous system cancer in adults. It is classified based on molecular alterations, notably the IDH1.R132H mutation, which helps in grouping lesions into different prognostic categories. Traditionally, gliomas are diagnosed through neuroimaging and subsequent tissue biopsies, which include surgical biopsies or resections. These methods, while standard, carry procedural risks and may not capture the full complexity and variability of the tumor. Moreover, knowing the IDH mutation status before surgery can guide the surgical approach. Researchers have now developed a blood test that detects tumor-derived extracellular RNA from just 2ml of blood, providing a minimally invasive diagnostic option.

The blood-based test, mt-IDHIdx, was developed by researchers at Massachusetts General Hospital (Boston, MA, USA) and validated across the study population (n=133) involving 133 individuals—80 with IDH1.R132H mutant gliomas, 44 with IDH1 wild-type gliomas, and nine healthy controls. The results from plasma testing published in Nature Communications show an overall sensitivity of 75.0% (95% CI: 64.1%–84.0%) and a specificity of 88.7% (95% CI: 77.0%–95.7%), with a positive predictive value of 90.9% and a negative predictive value of 70.1%, when compared to the traditional tissue-based methods. This blood-based testing not only serves diagnostic purposes but is also useful for ongoing monitoring and surveillance of the disease.

The workflow of this testing method is optimized, allowing for the analysis of tumor tissue and plasma samples to be completed in less than four hours from collection. With the ability to detect the IDH1 mutation from a blood sample, this approach enables non-invasive diagnosis and the monitoring of disease progression, treatment response, or recurrence. This breakthrough comes at a pivotal time as the FDA recently approved a new therapy, vorasidenib, targeting this mutation. Once the blood test is approved, it could significantly aid in selecting appropriate treatments and in managing patient care over time.

Related Links:
Massachusetts General Hospital

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Amoebiasis Test
ELI.H.A Amoeba
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.